Sirona Biochem Corp V.SBM

RE:October Updated Presentation

[Pandora]

Pareto8020 wrote:
https://www.sironabiochem.com/wp-content/uploads/2021/10/SBM-Investor-Presentation-October2021-1.pdf

TFC-1067 & family of skin lighteners
"In discussions with potential partners for global rights"

Hopefully this is the big pharma they were in discussions with last month about their high concentration version of TFC1067.  If they are scooping up the global rights that should have a substantial price tag attached to it.  If I were them I'd just buy the company in its entirety - at a premium (like 10x) to current shareprice. 

TFC-039
Phase I clinical trials completed - Wanbang/Fosun (China)

This is dumbfounding - how the hell have they completed the Phase I studies but Wanbang hasn't given SBM the information as per the contract?  I guess that is what you get when partnering with a firm in China - no cooperation and they've probably already divulged the tech to the State.  They took 7 years+ to do the Phase I now Howard has to nip at their heels and beg for the results - great partners.    

In return for the license of TFC-039, Wanbang are to provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC (Peoples Republic of China)
• To date, Sirona has received $1.5 M in milestone payments (Still short $8M)
• TFC-039 has completed Phase I clinical trials and results are being analyzed.
A delay in the analysis due to COVID 19 closures has been reported and acknowledged by Sirona.

Also:

Sirona is working intensively towards achieving the following
milestones:*

• Establish terms with global pharma company for rights to TFC-1067
• Establish terms with new organization in China for TFC-1067
• Receive terms for additional licensing agreement for the SGLT2 inhibitor in new markets
• Secure non-dilutive funding through anticipated collaborations
• Receive feedback on analysis from Phase I (from Wanbang) for the SGLT2 inhibitor
• Establish detailed project plan for scale-up and clinical trial of anti-aging compound
• File patents around novel compounds and therapy areas of interest
• Advance the anti-viral compounds into preclinical studies.

Below is the bailout statement re "timing" expectations (what we have been faced with for the past year):

*The milestones listed are not in chronological order.

The achievement of milestones is mostly dependent on external partners and factors over which we have limited control.

Accordingly, we will no longer provide a precise time estimate. We will immediately
update shareholders on material items as they arise.